Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase II, Phase ITissue collection/Repository, TreatmentActive18 and overNCINCI-2011-02015
CDR0000665415, S0905, U10CA032102, SWOG-S0905, NCT01064648

Trial Description

Summary

This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.

Further Study Information

OBJECTIVES:

I. To establish the maximum tolerated dose and the recommended phase II dose of cediranib maleate in combination with pemetrexed disodium and cisplatin in patients with malignant pleural mesothelioma. (Phase I) II. To compare the progression-free survival of patients treated with pemetrexed disodium and cisplatin with vs without cediranib maleate. (Phase II) III. To compare the overall survival of patients treated with these regimens. (Phase II) IV. To assess the safety and toxicity profile of these regimens. V. To assess the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (responsive or stable disease) using RECIST criteria and modified RECIST criteria for pleural tumors in a subset of patients with measurable disease. (Phase II) VI. To assess the rate of agreement between local and central pathology review of mesothelioma and its histologic subtypes. (Phase II) VII. To collect specimens for banking for use in future research studies. (Phase II)

OUTLINE: This is a multicenter, phase I dose-escalation study of cediranib maleate followed by a phase II randomized study. Patients enrolled in the phase II portion of the study are stratified according to Zubrod performance status (0-1 vs 2) and histologic subtype (epithelioid vs biphasic/sarcomatoid).

PHASE I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily at the maximum tolerated dose determined in phase I on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive pemetrexed disodium and cisplatin as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral placebo alone once daily in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up periodically for up to 3 years.

Eligibility Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed malignant pleural mesothelioma
  • Not planning to undergo surgical resection
  • Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by CT scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form
  • Zubrod performance status 0-2
  • ANC ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL (transfusion allowed)
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • SGOT or SGPT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases are present)
  • Serum creatinine ≤ 1.5 times ULN
  • Creatinine clearance ≥ 60 mL/min
  • Proteinuria ≤ +1 on 2 consecutive dipsticks taken ≥ 7 days apart
  • Repeat urinalysis not required provided first urinalysis shows no protein
  • Not pregnant or nursing
  • Fertile patients must agree to use effective contraception
  • Must be able to swallow oral medications
  • No mean QTc > 500 msec (with Bazett correction) by ECG or other significant ECG abnormality
  • No NYHA class III-IV congestive heart failure
  • No clinically significant hemoptysis, defined as > 1 tablespoon of bright red blood, within the past year
  • No known HIV infection
  • No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission.
  • No other concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer
  • No prior systemic therapy (chemotherapy or other biological therapy) for unresectable malignant pleural mesothelioma
  • Prior systemicchemotherapy or biologic therapy as neoadjuvant or adjuvant therapy allowed provided disease has recurred and systemic therapy was completed > 6 months before study entry
  • No prior therapy with any of the study drugs
  • At least 28 days since prior surgery (e.g., pleurectomy, pleurodeses, thoracic or other major surgeries) and recovered
  • At least 28 days since prior radiotherapy and recovered
  • No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)
  • No concurrent drugs or biologics with proarrhythmic potential
  • No concurrent major surgery

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

    Anne Tsao, Principal Investigator

    Trial Sites

    U.S.A.

    Arkansas
    Rogers

    Highlands Oncology Group - Bentonville

    Joseph Thaddeus Beck
    Ph: 800-381-6939

    California
    Antioch

    Kaiser Permanente - Deer Valley

    Louis Fehrenbacher
    Ph: 626-564-3455

    Fremont

    Kaiser Permanente - Fremont

    Louis Fehrenbacher
    Ph: 626-564-3455

    Fresno

    Kaiser Permanente Fresno Medical Center

    Louis Fehrenbacher
    Ph: 626-564-3455

    Los Angeles

    USC/Norris Comprehensive Cancer Center and Hospital

    Barbara J. Gitlitz
    Ph: 323-865-0451

    Barbara J. Gitlitz
    Ph: 323-865-0451

    Modesto

    Kaiser Permanente-Modesto

    Louis Fehrenbacher
    Ph: 626-564-3455

    Oakland

    Kaiser Permanente-Oakland

    Louis Fehrenbacher
    Ph: 626-564-3455

    Orange

    Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center

    Sai-Hong Ignatius Ou
    Ph: 877-827-8839
    Email: ucstudy@uci.edu

    Redwood City

    Kaiser Permanente Medical Center - Redwood City

    Louis Fehrenbacher
    Ph: 626-564-3455

    Richmond

    Kaiser Permanente Medical Center - Richmond

    Louis Fehrenbacher
    Ph: 626-564-3455

    Roseville

    Kaiser Permanente Medical Center - Roseville

    Louis Fehrenbacher
    Ph: 626-564-3455

    Sacramento

    Kaiser Permanente Medical Center - Sacramento

    Louis Fehrenbacher
    Ph: 626-564-3455

    South Sacramento Kaiser-Permanente Medical Center

    Louis Fehrenbacher
    Ph: 626-564-3455

    University of California Davis Cancer Center

    Karen Kelly
    Ph: 916-734-3089

    San Francisco

    Kaiser Permanente Medical Center - San Francisco Geary Campus

    Louis Fehrenbacher
    Ph: 626-564-3455

    San Jose

    Kaiser Permanente Medical Center - Santa Teresa

    Louis Fehrenbacher
    Ph: 626-564-3455

    San Leandro

    Kaiser Permanente Medical Center - Hayward

    Louis Fehrenbacher
    Ph: 626-564-3455

    San Rafael

    Kaiser Foundation Hospital - San Rafael

    Louis Fehrenbacher
    Ph: 626-564-3455

    Santa Clara

    Kaiser Permanente Medical Center - Santa Clara Homestead Campus

    Louis Fehrenbacher
    Ph: 626-564-3455

    Santa Rosa

    Kaiser Permanente Medical Center - Santa Rosa

    Louis Fehrenbacher
    Ph: 626-564-3455

    South San Francisco

    Kaiser Permanente Medical Center - South San Francisco

    Louis Fehrenbacher
    Ph: 626-564-3455

    Stockton

    Kaiser Permanente Medical Facility - Stockton

    Louis Fehrenbacher
    Ph: 626-564-3455

    Vacaville

    Kaiser Permanente Medical Center - Vacaville

    Louis Fehrenbacher
    Ph: 626-564-3455

    Vallejo

    Kaiser Permanente Medical Center - Vallejo

    Louis Fehrenbacher
    Ph: 626-564-3455

    Walnut Creek

    Kaiser Permanente Medical Center - Walnut Creek

    Louis Fehrenbacher
    Ph: 626-564-3455

    Connecticut
    Hartford

    Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Florida
    Orlando

    M.D. Anderson Cancer Center at Orlando

    Tirrell T Johnson
    Ph: 321-841-7246
    Email: CancerClinicalTrials@orlandohealth.com

    Hawaii
    Honolulu

    Kaiser Permanente - Moanalua Medical Center and Clinic

    Louis Fehrenbacher
    Ph: 626-564-3455

    Idaho
    Boise

    Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Coeur D'Alene

    Kootenai Medical Center

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Post Falls

    Kootenai Cancer Center - Post Falls

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Sandpoint

    Kootenai Cancer

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Illinois
    Bloomington

    Illinois CancerCare - Bloomington

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    St. Joseph Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Canton

    Illinois CancerCare - Canton

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Carbondale

    Memorial Hospital of Carbondale

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Carthage

    Illinois CancerCare - Carthage

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Centralia

    Centralia Oncology Clinic

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Decatur

    Cancer Care Center of Decatur

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    CCOP - Central Illinois

    Anne S Tsao
    Ph: 713-792-6363

    Decatur Memorial Hospital Cancer Care Institute

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Effingham

    Crossroads Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Eureka

    Illinois CancerCare - Eureka

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Galesburg

    Galesburg Clinic, PC

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    InterCommunity Cancer Center of Western Illinois

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Kewanee

    Illinois CancerCare - Kewanee Clinic

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Macomb

    Illinois CancerCare - Macomb

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Ottawa

    Illinois CancerCare - Ottawa

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Radiation Oncology of Northern Illinois

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Pekin

    Cancer Treatment Center at Pekin Hospital

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Illinois CancerCare - Pekin

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Peoria

    Illinois CancerCare - Peoria

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Methodist Medical Center of Illinois

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    OSF St. Francis Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Peru

    Illinois CancerCare - Princeton

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Valley Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Princeton

    Illinois CancerCare - Princeton

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Springfield

    Central Illinois Hematology Oncology Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Regional Cancer Center at Memorial Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Simmons Cooper Cancer Institute

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Springfield Clinic - Main Campus

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Swansea

    Cancer Care Specialists of Illinois-Swansea

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Michigan
    Ann Arbor

    Saint Joseph Mercy Cancer Center

    Philip J. Stella
    Ph: 734-712-4673

    University of Michigan Comprehensive Cancer Center

    Anne S Tsao
    Ph: 713-792-6363

    Dearborn

    Oakwood Cancer Center at Oakwood Hospital and Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Detroit

    Josephine Ford Cancer Center at Henry Ford Hospital

    Robert Anthony Chapman
    Ph: 313-916-1784

    Van Elslander Cancer Center at St. John Hospital and Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Wayne State University

    Shirish M. Gadgeel
    Ph: 313-576-9363

    Farmington Hills

    Weisberg Cancer Treatment Center

    Shirish M. Gadgeel
    Ph: 313-576-9363

    Flint

    Genesys Hurley Cancer Institute

    Philip J. Stella
    Ph: 734-712-4673

    Hurley Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Jackson

    Gayle M. Jacob Cancer Center at Allegiance Health

    Philip J. Stella
    Ph: 734-712-4673

    Lansing

    Sparrow Regional Cancer Center

    Philip J. Stella
    Ph: 734-712-4673

    Livonia

    St. Mary Mercy Hospital

    Philip J. Stella
    Ph: 734-712-4673

    Pontiac

    St. Joseph Mercy Oakland

    Philip J. Stella
    Ph: 734-712-4673

    Port Huron

    Mercy Regional Cancer Center at Mercy Hospital

    Philip J. Stella
    Ph: 734-712-4673

    Saginaw

    Seton Cancer Institute at Saint Mary's - Saginaw

    Philip J. Stella
    Ph: 734-712-4673

    Warren

    St. John Macomb Hospital

    Philip J. Stella
    Ph: 734-712-4673

    Mississippi
    Pascagoula

    Regional Cancer Center at Singing River Hospital

    James E. Clarkson
    Ph: 228-809-5292

    Missouri
    Bonne Terre

    Parkland Health Center-Bonne Terre

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Cape Girardeau

    Saint Francis Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Southeast Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Jefferson City

    Goldschmidt Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Saint Louis

    Missouri Baptist Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Sainte Genevieve

    Sainte Genevieve County Memorial Hospital

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Sullivan

    Missouri Baptist Sullivan Hospital

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Sunset Hills

    Missouri Baptist Outpatient Center-Sunset Hills

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Montana
    Billings

    Billings Clinic Cancer Center - 801 N 29th Street

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    CCOP - Montana Cancer Consortium

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    St. Vincent Healthcare Cancer Care Services

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Bozeman

    Bozeman Deaconess Cancer Center

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Butte

    St. James Healthcare Cancer Care

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Great Falls

    Benefis Sletten Cancer Institute

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Helena

    St. Peter's Hospital

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Kalispell

    Kalispell Regional Medical Center

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Missoula

    Community Medical Center

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    North Carolina
    Charlotte

    Carolina Surgical Clinic of Charlotte, PA

    Justin P Favaro
    Ph: 704-384-5369

    Oncology Specialists of Charlotte

    Justin P Favaro
    Ph: 704-384-5369

    Presbyterian Cancer Center at Presbyterian Hospital

    Justin P Favaro
    Ph: 704-384-5369

    Southern Oncology Specialists

    Justin P Favaro
    Ph: 704-384-5369

    Hendersonville

    Comprehensive Cancer Center at Pardee Hospital

    James E. Radford
    Ph: 828-696-4716

    Hendersonville Hematology and Oncology

    James E. Radford
    Ph: 828-696-4716

    Huntersville

    Lake Norman Hematology Oncology Specialists-Huntersville

    Justin P Favaro
    Ph: 704-384-5369

    Southern Oncology Specialists

    Justin P Favaro
    Ph: 704-384-5369

    Matthews

    Matthews Hematology Oncology Associates

    Justin P Favaro
    Ph: 704-384-5369

    Southeast Radiation Oncology Group, PA at Matthews Radiation Oncology Center

    Justin P Favaro
    Ph: 704-384-5369

    Mooresville

    Lake Norman Hematology Oncology Specialists

    Justin P Favaro
    Ph: 704-384-5369

    Statesville

    Iredell Memorial Hospital

    Ruby A. Grimm
    Ph: 704-873-5661

    Winston-Salem

    CCOP - Southeast Cancer Control Consortium

    Anne S Tsao
    Ph: 713-792-6363

    Ohio
    Belpre

    Strecker Cancer Center-Belpre

    J. Philip Kuebler
    Ph: 614-566-3275

    Chillicothe

    Adena Regional Medical Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Columbus

    Columbus Oncology Associates, Incorporated

    J. Philip Kuebler
    Ph: 614-566-3275

    Doctors Hospital at Ohio Health

    J. Philip Kuebler
    Ph: 614-566-3275

    Grant Medical Center Cancer Care

    J. Philip Kuebler
    Ph: 614-566-3275

    Mount Carmel Health - West Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Riverside Methodist Hospital Cancer Care

    J. Philip Kuebler
    Ph: 614-566-3275

    Zangmeister Center

    J. Philip Kuebler
    Ph: 800-446-5532

    Delaware

    Delaware Health Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Delaware Radiation Oncology

    J. Philip Kuebler
    Ph: 614-566-3275

    Grady Memorial Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Lancaster

    Fairfield Medical Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Marietta

    Strecker Cancer Center at Marietta Memorial Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Mount Vernon

    Knox Community Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Newark

    Licking Memorial Cancer Care Program at Licking Memorial Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Newark Radiation Oncology

    J. Philip Kuebler
    Ph: 614-566-3275

    Portsmouth

    Southern Ohio Medical Center Cancer Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Springfield

    Community Hospital of Springfield and Clark County

    J. Philip Kuebler
    Ph: 614-566-3275

    Westerville

    Mount Carmel St. Ann's Cancer Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Zanesville

    Genesis - Good Samaritan Hospital

    J. Philip Kuebler
    Ph: 614-488-2745
    Email: sheree@columbusccop.org

    Oregon
    Clackamas

    Clackamas Radiation Oncology Center

    Alison K Conlin
    Ph: 503-215-6412

    Newberg

    Providence Newberg Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Oregon City

    Willamette Falls Hospital

    Alison K Conlin
    Ph: 503-215-6412

    Portland

    Providence Cancer Center at Providence Portland Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Providence St. Vincent Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Southwest Oncology Group

    Anne S Tsao
    Email: astsao@mdanderson.org

    South Carolina
    Easley

    Cancer Centers of the Carolinas - Easley

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Greenville

    Cancer Centers of the Carolinas - Andrews

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Cancer Centers of the Carolinas - Faris Road

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Cancer Centers of the Carolinas - Grove Commons

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    CCOP - Greenville

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Greenville Memorial Hospital

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Greer

    Cancer Centers of the Carolinas - Greer Radiation Oncology

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Seneca

    Cancer Centers of the Carolinas - Seneca

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Spartanburg

    Cancer Centers of the Carolinas - Spartanburg

    Jeffrey Kent Giguere
    Ph: 864-241-6251

    Tennessee
    Kingsport

    Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center

    Asheesh Shipstone
    Ph: 423-578-8538

    Kingsport Hematology-Oncology Associates

    Asheesh Shipstone
    Ph: 423-578-8538

    Texas
    Houston

    Univeristy of Texas M.D. Anderson Cancer Center

    Anne S Tsao
    Ph: 713-792-3245

    San Antonio

    Southwest Oncology Group

    Anne S Tsao
    Email: astsao@mdanderson.org

    Virginia
    Danville

    Danville Hematology and Oncology, Incorporated

    Qiwei W Gai
    Ph: 434-793-0044

    Danville Regional Medical Center

    Timothy W. Brotherton
    Ph: 434-793-0044

    Norton

    Southwest Virginia Regional Cancer Center at Wellmonth Health

    Asheesh Shipstone
    Ph: 423-578-8538

    Washington
    Longview

    Lower Columbia Regional Cancer Center at PeaceHealth-St. John Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Vancouver

    Southwest Washington Medical Center Cancer Center

    Alison K Conlin
    Ph: 503-215-6412

    Wyoming
    Cody

    Big Horn Basin Cancer Center

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Billings Clinic-Cody

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Sheridan

    Welch Cancer Center at Sheridan Memorial Hospital

    Benjamin Thomas Marchello
    Ph: 800-648-6274

    Link to the current ClinicalTrials.gov record.
    NLM Identifier NCT01064648
    ClinicalTrials.gov processed this data on May 25, 2015

    Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.